Abstract
Cellular-based therapies have drawn a great deal of attention thanks to their regenerative medicine approaches to treat incurable diseases and specific injuries. In this regard, injectable cell delivery systems could actualize the therapeutically beneficial outcomes of cell-based therapeutic products. These systems have found considerable clinical uses. Hence, the recent studies have focused on developing injectable bio-constructs to protect transplanted cells during delivery and stimulating endogenous regeneration through interactions of these cells and host tissue. This paper introduces a framework, as a general concept, to improve cell delivery systems for cell-based therapeutic products. Studies on stable injectable carriers can enhance cell homing, proliferation, viability, dressing of irregular shape of target sites, and subsequently support transplanted cell functionality. However, more studies should be conducted on new technologies for the injectable cell-based product for cell delivery and the clinical applications.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsAbbreviations
- CAR-T cell:
-
Chimeric antigen receptor T cells
- CBER:
-
Center for Biologics Evaluation and Research
- CT:
-
Cell-based therapy
- DMEM:
-
Dulbecco’s Modified Eagle ́s Medium
- FDA:
-
U.S. food and drug administration
- GvHD:
-
Graft versus host disease
- MSCs:
-
Mesenchymal Stem Cells
- OTAT:
-
Tissues and Advanced Therapies
- RG:
-
Regenerative medicine
References
Amer MH (2017) Development of injectable cell delivery systems for high accuracy cell therapy applications. [cited 2019 May 5]. Available from: http://eprints.nottingham.ac.uk/39839/
Amer MH, Rose FRAJ, Shakesheff KM, Modo M, White LJ (2017) Translational considerations in injectable cell-based therapeutics for neurological applications: concepts, progress and challenges. npj Regen Med 2(1):23. [Internet] [cited 2019 Feb 27]. Available from: http://www.nature.com/articles/s41536-017-0028-x
Andtbacka RHI, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J et al (2015) Talimogene Laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol 33(25):2780–2788. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26014293
Bandeiras C, Cabral JM, Finkelstein SN, Ferreira FC (2018) Modeling biological and economic uncertainty on cell therapy manufacturing: the choice of culture media supplementation. Regen Med 13(8):917–933. [Internet] [cited 2019 Feb 8]. Available from: https://www.futuremedicine.com/doi/10.2217/rme-2018-0034
Barbash IM, Chouraqui P, Baron J, Feinberg MS, Etzion S, Tessone A et al (2003) Systemic delivery of bone marrow–derived mesenchymal stem cells to the infarcted myocardium. Circulation 108(7):863–868. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12900340
Belema-Bedada F, Uchida S, Martire A, Kostin S, Braun T (2008) Efficient homing of multipotent adult mesenchymal stem cells depends on FROUNT-mediated clustering of CCR2. Cell Stem Cell 2(6):566–575. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18522849
Chute JP (2006) Stem cell homing. Curr Opin Hematol 13(6):399–406. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17053451
Cooper JA, Bromley LM, Baranowski AP, Barker SGE (2000) Evaluation of a needle-free injection system for local anaesthesia prior to venous cannulation. Anaesthesia 55(3):247–250. [Internet] [cited 2019 Feb 26]. Available from: http://doi.wiley.com/10.1046/j.1365-2044.2000.01210.x
Cuende N, Rasko JEJ, Koh MBC, Dominici M, Ikonomou L (2018) Cell, tissue and gene products with marketing authorization in 2018 worldwide. Cytotherapy 20(11):1401–1413. [Internet] [cited 2019 Jun 3]. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1465324918306194
DeRenzo C, Gottschalk S (2019) Genetic modification strategies to enhance CAR T cell persistence for patients with solid tumors. Front Immunol 10:218. [Internet] [cited 2019 May 2]. Available from: https://www.frontiersin.org/article/10.3389/fimmu.2019.00218/full
Devasani S, Dev A, Rathod S, Deshmukh GR (2016) An overview of in situ gelling systems. [Internet] [cited 2019 May 4]. Available from: https://www.semanticscholar.org/paper/An-overview-of-in-situ-gelling-systems-Devasani-Dev/6c239f86991156ad22cdc4af8dcdbbd231902ab5
Dimatteo R, Darling NJ, Segura T (2018) In situ forming injectable hydrogels for drug delivery and wound repair. Adv Drug Deliv Rev 127:167–184. [Internet] [cited 2019 May 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29567395
Farrell K, Joshi J, Kothapalli CR (2017) Injectable uncrosslinked biomimetic hydrogels as candidate scaffolds for neural stem cell delivery. J Biomed Mater Res Part A 105(3):790–805. [Internet] [cited 2017 Oct 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27798959
Gill S, Maus MV, Porter DL (2016) Chimeric antigen receptor T cell therapy: 25 years in the making. Blood Rev 30(3):157–167. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26574053
Golchin A, Farahany TZ (2019) Biological products: cellular therapy and FDA approved products. Stem Cell Rev Rep 15:1–10. [Internet]. [cited 2019 Jan 10]. Available from: http://link.springer.com/10.1007/s12015-018-9866-1
Golchin A, Hosseinzadeh S, Roshangar L (2017) The role of nanomaterials in cell delivery systems. Med Mol Morphol 51(1):1–12. [Internet] [cited 2018 Jan 17]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29170827
Golchin A, Hosseinzadeh S, Ardeshirylajimi A (2018a) The exosomes released from different cell types and their effects in wound healing. J Cell Biochem 119(7):5043–5052. [Internet] [cited 2018 Mar 28]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29377240
Golchin A, Rekabgardan M, Taheri RA, Nourani MR (2018b) Promotion of cell-based therapy: special focus on the cooperation of mesenchymal stem cell therapy and gene therapy for clinical trial studies. In: Turksen K (ed) Cell Biology and Translational Medicine, Volume 4 Advances in Experimental Medicine and Biology, vol 1119. Springer, Cham, pp 103–118. [Internet] [cited 2019 Jun 4]. Available from: http://link.springer.com/10.1007/5584_2018_256
Golchin A, Hosseinzadeh S, Staji M, Soleimani M, Ardeshirylajimi A, Khojasteh A (2019) Biological behavior of the curcumin incorporated chitosan/poly(vinyl alcohol) nanofibers for biomedical applications. J Cell Biochem. [Internet] [cited 2019 Jun 4]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jcb.28808
Han X, Bryson PD, Zhao Y, Cinay GE, Li S, Guo Y et al (2017) Masked chimeric antigen receptor for tumor-specific activation. Mol Ther 25(1):274–284. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28129121
Hung S-C, Pochampally RR, Hsu S-C, Sanchez C, Chen S-C, Spees J et al (2007) Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One 2(5):e416. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/17476338
Karp JM, Leng Teo GS (2009) Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 4(3):206–216. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/19265660
Kim B-S, Cho C-S (2018) Injectable hydrogels for regenerative medicine, Tissue Eng Regen Med. 15(5):511–512. [Internet] [cited 2019 May 4]. Available from: http://link.springer.com/10.1007/s13770-018-0161-7
Knochelmann HM, Smith AS, Dwyer CJ, Wyatt MM, Mehrotra S, Paulos CM (2018) CAR T Cells in solid tumors: blueprints for building effective therapies. Front Immunol 9:1740. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30140266
Kumar S, Ponnazhagan S (2007) Bone homing of mesenchymal stem cells by ectopic α4 integrin expression. FASEB J 21(14):3917–3927. [Internet] [cited 2019 May 2]. Available from: http://www.fasebj.org/doi/10.1096/fj.07-8275com
Kumar C, Kohli S, Chiliveru S, Bapsy PP, Jain M, Suresh Attili VS et al (2017) A retrospective analysis comparing APCEDEN® dendritic cell immunotherapy with best supportive care in refractory cancer. Immunotherapy 9(11):889–897. [Internet] [cited 2019 Jun 3]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28838282
Kurtz A (2008) Mesenchymal stem cell delivery routes and fate. Int J Stem Cells 1(1):1–7. [Internet] [cited 2017 Apr 23]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24855503
Lapidot T, Dar A, Kollet O (2005) How do stem cells find their way home? Blood 106(6):1901–1910. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15890683
Lapteva L, Vatsan R, Purohit-Sheth T (2018) Regenerative medicine therapies for rare diseases. Transl Sci Rare Dis 3(3–4):121–132. [Internet] [cited 2019 Feb 8]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30613470
Li J, Mooney DJ (2016) Designing hydrogels for controlled drug delivery. Nat Rev Mater 1(12):16071. [Internet] [cited 2019 May 4]. Available from: http://www.nature.com/articles/natrevmats201671
Liow SS, Dou Q, Kai D, Karim AA, Zhang K, Xu F et al (2016) Thermogels: in situ gelling biomaterial. ACS Biomater Sci Eng 2(3):295–316. [Internet] [cited 2019 May 4]. Available from: http://pubs.acs.org/doi/10.1021/acsbiomaterials.5b00515
Lopes AG, Sinclair A, Frohlich B (2018) Cost analysis of cell therapy manufacture: autologous cell therapies, part 2. BioProcess Int. [Internet] [cited 2019 Feb 8]. Available from: https://bioprocessintl.com/manufacturing/cell-therapies/cost-analysis-of-cell-therapy-manufacturing-autologous-cell-therapies-part-2/
Mahla RS (2016) Stem cells applications in regenerative medicine and disease therapeutics. Int J Cell Biol 2016(1):–24. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27516776
Marquardt LM, Heilshorn SC (2016a) Design of injectable materials to improve stem cell transplantation. Curr Stem Cell Rep 2(3):207–220. [Internet] [cited 2019 May 4]. Available from: http://link.springer.com/10.1007/s40778-016-0058-0
Marquardt LM, Heilshorn SC (2016b) Design of injectable materials to improve stem cell transplantation. Curr Stem Cell Rep 2(3):207–220. [Internet] [cited 2019 May 5]. Available from: http://link.springer.com/10.1007/s40778-016-0058-0
Martinez M, Moon EK (2019) CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment. Front Immunol 10:128. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30804938
Morgan MA, Schambach A (2018) Engineering CAR-T cells for improved function against solid tumors. Front Immunol 9. [Internet] [cited 2019 May 2]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6217729/
Peltzer J, Aletti M, Frescaline N, Busson E, Lataillade J-J, Martinaud C (2018) Mesenchymal stromal cells based therapy in systemic sclerosis: rational and challenges. Front Immunol 9:2013. [Internet] [cited 2019 Feb 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30271402
Ponte AL, Marais E, Gallay N, Langonné A, Delorme B, Hérault O et al (2007) The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells 25(7):1737–1745. [Internet] [cited 2019 May 2] Available from: http://www.ncbi.nlm.nih.gov/pubmed/17395768
Press Announcements – FDA awards 12 grants to fund new clinical trials to advance the development of medical products for the treatment of rare diseases. [cited 2019 Feb 8]; Available from: https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm621490.htm
Research C for BE and. Cellular and Gene Therapy Products. 2018 [cited 2018 May 6]. Available from: https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/default.htm
Ruster B, Gottig S, Ludwig RJ, Bistrian R, Muller S, Seifried E et al (2006) Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 108(12):3938–3944. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16896152
Schmidt C (2011) FDA approves first cell therapy for wrinkle-free visage. Nat Biotechnol 29(8):674–675. [Internet] [cited 2018 May 6]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21822225
Shin J-Y, Yoon J-K, Noh MK, Bhang SH, Kim B-S (2016) Enhancing therapeutic efficacy and reducing cell dosage in stem cell transplantation therapy for ischemic limb diseases by modifying the cell injection site. Tissue Eng Part A 22(3–4):349–362. [Internet] [cited 2019 Feb 25]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26824782
Sohni A, Verfaillie CM (2013) Mesenchymal stem cells migration homing and tracking. Stem Cells Int 2013:130763. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24194766
Wyles SP, Hayden RE, Meyer FB, Terzic A (2019) Regenerative medicine curriculum for next-generation physicians. npj Regen Med 4(1):3. [Internet] [cited 2019 Feb 7]. Available from: http://www.nature.com/articles/s41536-019-0065-8
Xia L, McDaniel JM, Yago T, Doeden A, McEver RP (2004) Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 104(10):3091–3096. [Internet] [cited 2019 May 2]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15280192
Zhang Z (2017) Injectable biomaterials for stem cell delivery and tissue regeneration. Expert Opin Biol Ther 17(1):49–62. [Internet] [cited 2019 May 4]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27805430
Acknowledgement
This study is related to the project NO. 1397/69252 From Student Research Committee, Shahid Beheshti University of Medical Sciences, Tehran, Iran. We also appreciate the “Student Research Committee” and “Research & Technology Chancellor” in Shahid Beheshti University of Medical Sciences for their financial support of this study.
Author Contributions
A.G. conceptualized the outline and contents of the article. All authors contributed to writing and editing the manuscript. S.H. had an advisory role.
Conflict of Interest
Authors don’t have conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Golchin, A., Shams, F., Kangari, P., Azari, A., Hosseinzadeh, S. (2019). Regenerative Medicine: Injectable Cell-Based Therapeutics and Approved Products. In: Turksen, K. (eds) Cell Biology and Translational Medicine, Volume 7. Advances in Experimental Medicine and Biology(), vol 1237. Springer, Cham. https://doi.org/10.1007/5584_2019_412
Download citation
DOI: https://doi.org/10.1007/5584_2019_412
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-37844-8
Online ISBN: 978-3-030-37845-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)